These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 24053202)
1. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. Lengfelder E; Hofmann WK; Nowak D Expert Rev Anticancer Ther; 2013 Sep; 13(9):1035-43. PubMed ID: 24053202 [TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
3. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811 [TBL] [Abstract][Full Text] [Related]
4. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Lengfelder E; Hofmann WK; Nowak D Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379 [TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Grimwade D; Mistry AR; Solomon E; Guidez F Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821 [TBL] [Abstract][Full Text] [Related]
7. What is the role of arsenic in newly diagnosed APL? Tallman MS Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605 [TBL] [Abstract][Full Text] [Related]
8. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
11. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474 [TBL] [Abstract][Full Text] [Related]
12. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197 [TBL] [Abstract][Full Text] [Related]
14. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361 [TBL] [Abstract][Full Text] [Related]
15. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080 [TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. Bergstrom SK; Gillan E; Quinn JJ; Altman AJ J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675 [TBL] [Abstract][Full Text] [Related]
17. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444 [TBL] [Abstract][Full Text] [Related]
18. [Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)]. Moreno Tejero ML; Lassaletta Atienza A; García Salido A; Sevilla Navarro J; Madero López L An Pediatr (Barc); 2010 Jul; 73(1):39-41. PubMed ID: 20605542 [TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103 [TBL] [Abstract][Full Text] [Related]
20. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ; N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]